NICE issues draft guidance on crizanlizumab for preventing sickle cell crises in sickle cell disease for consultation

In DRAFT guidance, NICE does not recommend crizanlizumab for preventing recurrent sickle cell crises in people aged ≥16 with sickle cell disease. The evidence of benefit is uncertain and the most likely cost-effectiveness estimates are substantially higher than the NICE threshold

National Institute for Health and Care Excellence